Background: Endometrial cancer (EC) is one of the most common gynecological malignancies. Pathological parameters such as lymphovascular space invasion (LVSI) and depth of myometrial invasion are key factors for staging, risk assessment, and therapeutic decision-making. In recent years, molecular classification, including the evaluation of p53 status, has further refined risk stratification. Although p53 alterations have been associated with aggressive pathological features, real-world data exploring their relationship with clinicopathological characteristics remain limited. This study evaluates the relationship between p53 status and markers of tumour aggressiveness in a real-world cohort of EC. Material (patients) and Methods: Clinical, histopathological, and immunohistochemical data were collected for 100 patients diagnosed with endometrial cancer prospectively enrolled within a PRIN 2022 project funded by MUR. Tumour grade, histological subtype, LVSI, depth of myometrial invasion, and stage were recorded. Patients were stratified into endometrioid and non-endometrioid groups according to histological subtype, and disease stage was categorized as early (FIGO I–II) or advanced (FIGO III–IV). p53 status was assessed by immunohistochemistry and classified as altered or wild-type. Results: p53 alterations were more frequently observed in non-endometrioid tumours compared to endometrioid tumours (80.0% vs 10.7%; χ2, p < 0.001). In addition, p53-altered tumours showed a higher proportion of highgrade disease (75.0% vs 26.4%; χ2, p < 0.001) and LVSI was also more frequent in p53-altered tumours (57.1% vs 37.5%; χ2, p = 0.003). No substantial differences were observed in the depth of myometrial invasion between p53-altered and wild-type tumours (χ2, p = 0.16). A higher proportion of advanced-stage disease was observed in p53-altered tumours (35.7% vs 19.4%), although this association is not significant (χ2, p = 0.15). Overall, these findings indicate a consistent association between p53 alteration and multiple features of tumour aggressiveness. Conclusions: In this real-world cohort, p53 alteration was associated with unfavourable histology, higher tumour grade, and other markers of aggressive disease. These findings are consistent with previous evidence and provide additional real-world data supporting the integration of immunohistochemical and pathological features to refine risk stratification in EC.
p53 alteration identifies aggressive pathological features in endometrial cancer: a real-world cohort study
Lombardo Valentina Nunziella;Scandurra Giuseppa;Aiello Fabio;Priulla Andrea;Spadola Saveria;Scollo Paolo;Capoluongo Ettore Domenico.
2026-01-01
Abstract
Background: Endometrial cancer (EC) is one of the most common gynecological malignancies. Pathological parameters such as lymphovascular space invasion (LVSI) and depth of myometrial invasion are key factors for staging, risk assessment, and therapeutic decision-making. In recent years, molecular classification, including the evaluation of p53 status, has further refined risk stratification. Although p53 alterations have been associated with aggressive pathological features, real-world data exploring their relationship with clinicopathological characteristics remain limited. This study evaluates the relationship between p53 status and markers of tumour aggressiveness in a real-world cohort of EC. Material (patients) and Methods: Clinical, histopathological, and immunohistochemical data were collected for 100 patients diagnosed with endometrial cancer prospectively enrolled within a PRIN 2022 project funded by MUR. Tumour grade, histological subtype, LVSI, depth of myometrial invasion, and stage were recorded. Patients were stratified into endometrioid and non-endometrioid groups according to histological subtype, and disease stage was categorized as early (FIGO I–II) or advanced (FIGO III–IV). p53 status was assessed by immunohistochemistry and classified as altered or wild-type. Results: p53 alterations were more frequently observed in non-endometrioid tumours compared to endometrioid tumours (80.0% vs 10.7%; χ2, p < 0.001). In addition, p53-altered tumours showed a higher proportion of highgrade disease (75.0% vs 26.4%; χ2, p < 0.001) and LVSI was also more frequent in p53-altered tumours (57.1% vs 37.5%; χ2, p = 0.003). No substantial differences were observed in the depth of myometrial invasion between p53-altered and wild-type tumours (χ2, p = 0.16). A higher proportion of advanced-stage disease was observed in p53-altered tumours (35.7% vs 19.4%), although this association is not significant (χ2, p = 0.15). Overall, these findings indicate a consistent association between p53 alteration and multiple features of tumour aggressiveness. Conclusions: In this real-world cohort, p53 alteration was associated with unfavourable histology, higher tumour grade, and other markers of aggressive disease. These findings are consistent with previous evidence and provide additional real-world data supporting the integration of immunohistochemical and pathological features to refine risk stratification in EC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


